Table 2.
Symptoms, clinical table, treatment, need for hospitalization and intensive care, development of AKI and need for RRT in COVID-19 group
| n (%) | |
|---|---|
| Symptoms | |
| Cough | 127/168 (% 75.6) |
| Dyspnea | 111/169 (% 65.7) |
| Fever | 105/170 (% 61.8) |
| Sore throat | 64/163 (%39.3) |
| Loss of taste | 22/151 (% 14.6) |
| Loss of smell | 21/153 (%13.7) |
| Diarrhea | 14/157 (% 8.9) |
| Asymptomatic | 5/156 (% 3.2) |
| COVID-19 related clinical table at the time of diagnosis | |
| Asymptomatic disease | 14/173 (%8.1) |
| Mild disease | 61/173 (%35.3) |
| Medium-severe disease | 89/173 (% 51.4) |
| Severe-vital disease | 9/173 (%5.2) |
| Treatment for COVID-19 | |
| Favipiravir | 144/172 (%83.7) |
| Glucocorticoid | 71/166 (42.8) |
| Macrolide | 57/165 (34.5) |
| Hydroxychloroquine | 51/167 (30.5) |
| Oseltamivir | 22/166 (13.3) |
| Tocilizumab | 7/163 (4.3) |
| Convalescent plasma | 2/163 (1.2) |
| Apheresis/immunabsorption | 1/164 (0.6) |
| Anakinra/Canakinumab | 1/164 (0.6) |
| JAK2 inhibitor | 1/164 (0.6) |
| Other | 8/164 (4.9) |
| Inpatient treatment | 126/173 (% 72.8) |
| Development of AKI in hospitalized patients | 69/126 (% 54.8) |
| Stage 1 AKI (KDIGO) | 40/69 (58) |
| Stage 2 AKI (KDIGO) | 19/69 (27.5) |
| Stage 3 AKI (KDIGO) | 10/69 (14.5) |
| AKI Development of need for dialysis in hospitalized patients | 10/126 (%7.9) |
| ICU need | 21/126 (16.7) |
| Non-invasive mechanical ventilation | 18/22 (81.8) |
| Intubation | 8/22 (36.4) |
| ECMO | 2/21(9.5) |
| Total length of stay in hospital (days) | 10 (8–15) |
COVID-19 coronavirus disease 2019, JAK2 janus kinase, AKI acute kidney injury, KDIGO kidney disease improving global outcomes, ECMO extracorporeal membrane oxygenation, RRT renal replacement therapy